Dexcom
CompanyUnited StatesFounded 1999
Dexcom develops 2 assets, the furthest in human trials (Stelo glucose biosensor in polycystic ovarian syndrome). Mostly device; based in the United States, founded in 1999.
- 2
- Assets
- Furthest stage
- Human trials
- 0
- Trials
- 2
- Signals
Pipeline
2Continuous glucose biosensor measuring interstitial glucose levels
Human trials, Device, polycystic ovarian syndrome
Continuously measures interstitial glucose to provide glucose profiles and metabolic health insights.
Stage not known, Device
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- People1
- Signals20
Papers
JMIR research protocols, 16 Oct 2026
ADA Scientific Sessions 2026 abstract, 11 Jun 2026
ADA Scientific Sessions 2026 abstract, 8 Jun 2026
Dynamic CGM Models to Predict GDM: A GO MOMs Analysis
ADA Scientific Sessions 2026 abstract, 7 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
A Circulating microRNA Signature for Familial Risk of Type 2 Diabetes and Renal Failure
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
More Than Hot Flashes: Menopause Stages and Diabetes Management Burden
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Gestational Glucose Intolerance and Incident Maternal Hypertension
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Assessing Advanced Glycation Endproducts Using a Wearable Health Monitoring Device
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Early Insulin Resistance Is a Stronger Predictor of Early than Late Gestational Diabetes
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Continuous Glucose Monitoring as Assessment Tool for Diagnosis of Prediabetes State
ADA Scientific Sessions 2026 abstract, 5 Jun 2026